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The ‘omics’-era is well and truly upon us. Driven by
technological innovations, fields such as genetics, epige-
netics, proteomics and imaging are advancing at tremen-
dous pace and in addition to unraveling pathophysiological
mechanisms of health and disease, also reveal the
increasingly complex biology that forms the basis of living
systems. In this issue of the European Journal of Epi-
demiology, Nishihara and colleagues describe ‘molecular
pathological epidemiology’, a relatively novel sub-field
within epidemiology that examines the association between
a risk factor and disease by taking into account the inherent
pathological (and often molecular) heterogeneity of a dis-
ease [1]. Molecular pathological epidemiology had its
original applications in oncology, but—driven by omics-
research—is now quickly disseminating to other fields of
biomedical research. Molecular pathological epidemiology
holds great promise by bringing together epidemiology and
molecular biology, two fields that traditionally have been
considered at the opposite extremes of the biomedical
research spectrum. It is expected that in coming years
molecular pathological epidemiology will importantly
shape the way, in which omics-research is conducted and
interpreted.
In their paper, Nishihara et al. [1] use molecular
pathological epidemiology to elucidate biomedical para-
doxes that hitherto were ascribed to methodological phe-
nomena, such as selection bias, collider bias, unmeasured
confounding and reverse causality. They show that
paradoxical associations that have been found between a
risk factor for disease and prognosis after disease-onset
might in fact be reflecting true underlying biology rather
than being an artifact of study design. While the focus of
their paper is on examples that elegantly illustrate the
application of molecular pathological epidemiology to
unravel methodological paradoxes, I believe this approach
will have further-reaching implications in biomedical
research, which are only briefly touched upon by Nishihara
et al. and which I will expand on below.
First, I am convinced that molecular pathological epi-
demiology is a pivotal cornerstone for successful imple-
mentation of novel initiatives, such as ‘personalized
medicine’ and its latest incarnation ‘precision medicine’.
Precision medicine is probably an overhyped concept at the
moment, but nonetheless does signal the direction in which
clinical medicine should develop to reach the next level.
The basic concept of precision medicine is that each
individual has his or her own unique set of characteristics
that together cause disease or determine prognosis. This
unique set therefore requires a unique approach to clinical
management, tailor-made for that individual patient [2].
The continued success of omics-research through novel
discoveries will lead to rapid expansion of the known set of
characteristics that determine disease and thereby increase
the precision of precision medicine. Interestingly, this
framework for disease causation was formalized in the
epidemiological literature already as far back as the sev-
enties [3]. As such, precision medicine is nothing new for
epidemiology. In fact, the enthusiasm with which precision
medicine has been heralded by various stake-holders and
policy makers could and should be considered a vindica-
tion for the epidemiological way of thinking about disease.
What is worrying though is that the role of the epidemi-
ologist in precision medicine seems so far to be ill-defined.
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Yet, given the challenges that precision medicine faces for
correct design and interpretation of its research (indeed,
consider the paradoxical findings that can only be tackled
by proper understanding of molecular pathological epi-
demiology and other epidemiological concepts), I would
expect the epidemiologist to be at the fore-front of preci-
sion medicine. Therefore, now is the time for epidemiol-
ogists to assume a pro-active role in the process of
developing and implementing precision medicine.
The second implication of molecular pathological epi-
demiology relates to a core activity in clinical medicine.
Diagnosis of disease (and the efforts to achieve that) forms
a major milestone in the clinical management of any
patient and in fact much—if not most—effort in clinical
practice is dedicated at establishing an accurate diagnosis.
Diagnoses of diseases are usually based on a set of signs
and symptoms that typically occur together in a patient and
as such are considered a separate disease entity. Very often,
diagnostic criteria also include the presumed underlying
etiology, thereby forming the basis of etiologic subtyping.
Examples include subtyping of ischemic stroke into large
vessel, small vessel, or cardioembolic stroke and
polyneurpathy into various subgroups, such as diabetic
polyneuropathy. Such subclassifications have been devel-
oped for several decades and though very useful for con-
temporary clinical management, neglect the multifactorial
nature of diseases [2]. Consequently, the underlying pre-
sumed etiology is neither sensitive nor specific enough to
justify a single dedicated subcategory. For instance, most
stroke patients will have a certain degree of small vessel
pathology and it therefore remains arbitrary what burden of
small vessel pathology warrants the designation of a stroke
as small vessel stroke. Molecular pathological epidemiol-
ogy can provide an etiologic framework for diseases, which
does allow for etiologic subtyping. Taking examples from
Nishihara et al. it can be justified to subclassify colorectal
into two types based on presence or absence of the
rs4939837 variant in the SMAD7-gene or subtyping renal
cell carcinoma based on up- or downregulation of fatty acid
synthase. After all, rs4939837 and up- or downregulation
of fatty acide synthase may act as criteria sensitive and
specific enough to distinguish the two subtypes. Omics-
research will continue to further unravel many complex
diseases and therefore expand the possibilities for etio-
logical subtyping. Therefore, now is the time to re-write
medical textbooks and incorporate molecular pathological
epidemiology into mainstream biomedical literature.
Just like any other field, epidemiology too needs to keep
up with the technology-push in research. Molecular
pathological epidemiology might just be the trigger that
helps epidemiology firmly establish its role in the omics-
era.
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